Atf6 polymorphisms associated with myocardial infarction, method of detection and uses thereof
CA 2936612 C · Owner: Celera Corporation · Inventors: Devlin, James J.; Iakoubova, Olga; Cargill, Michele
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is based on the discovery of genetic polymorphisms that are associated with myocardial infarction. In particular the present invention relates to nucleic acid molecules containing the polymorphisms variant proteins encoded by such nucleic acid molecules reagents for detecting the polymorphic nucleic acid molecules and proteins and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. Figure 1 provides a diagrammatic representation of a computer-based discovery system containing the SNP information of the present invention in computer readable form.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 22, 2003 and granted November 21, 2017. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 22, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 22, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.